目的 分析咸阳市中心医院吸入制剂应用情况，为患者及临床使用提供参考。方法 对2018—2020年咸阳市中心医院肺部吸入制剂的种类、销售额、用药频度（DDDs）、日均费用（DDC）和药品使用排序比（B/A）进行统计分析。结果 2018—2020年咸阳市中心医院肺部吸入制剂的用药金额呈逐年上升趋势，总金额的构成比基本保持稳定。其中总金额排前3位的制剂分别为吸入用布地奈德混悬液、布地奈德福莫特罗粉吸入剂、吸入用复方异丙托溴铵；DDDs排名前3位的制剂分别是布地奈德福莫特罗粉吸入剂、吸入用布地奈德混悬液、噻托溴铵粉吸入剂；DDC排名前3位的制剂分别是吸入用复方异丙托溴铵溶液、吸入用布地奈德混悬液、布地奈德福莫特罗粉吸入剂；B/A值均低于2。结论 2018—2020年度咸阳市中心医院肺部吸入制剂使用及价格结构较为合理。

Objective To investigate the application of pulmonary inhalers in Xianyang Central Hospital,and to provide reference for rational drug use in clinic. Methods The utilization of pulmonary inhalers in Xianyang Central Hospital from 2018 to 2020 was analyzed statistically in respects of drug types, consumption sum, DDDs, DDC, rank ratios of total consumption, and B/A. Results Consumption sum of pulmonary inhalers had a rising trend from 2018 to 2020, but the proportions of pulmonary inhaler in the total drug use were kept stable. The top 3 drug of consumption sum were Budesonide Suspension for inhalation, Budesonide and Formoterol Fumarate Powder for inhalation, and Compound Ipratropium Bromide Solution for inhalation. The top 3 drugs of DDDs were Budesonide and Formoterol Fumarate Powder for inhalation, Budesonide Suspension for inhalation, and Tiotropium Bromide Powder for inhalation. The top 3 drugs of DDC were Compound Ipratropium Bromide Solution for inhalation, Budesonide Suspension for inhalation, and Budesonide and Formoterol Fumarate Powder for inhalation. B/A of specific pulmonary inhalers were low to 2.00. Conclusion The overall drug use and the price structures in Xianyang Central Hospital from 2018 to 2020 are reasonable.

R974